🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The main objective of this study is to observe and evaluate the safety and ...
Status
Recruiting
Location
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Start Date
2025-05-30
Trial ID
NCT06980155
Treatments Being Tested
Phase II multicenter, Canadian only study - open to 25 subjects. Study open...
Status
Unknown
Location
Hospital Maissoneuve
Start Date
2016-03
Trial ID
NCT02519816
The purpose of this study is to evaluate the safety, tolerability and pharm...
Status
Completed
Location
Site US0006
Start Date
2014-10-14
Trial ID
NCT02175433
Treatments Being Tested
The purpose of this study is to evaluate the safety, tolerability, and prel...
Status
Active Not Recruiting
Location
University of Alabama At Birmingham
Start Date
2021-02-23
Trial ID
NCT04279847
Treatments Being Tested
This is a multicenter, safety and pharmacokinetic trial to determine the MT...
Status
Completed
Location
Children's Hospital Los Angeles
Start Date
2014-04-29
Trial ID
NCT01748149
Treatments Being Tested
This is an investigator-initiated, multi-center, open-label clinical study ...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-07-31
Trial ID
NCT06528249
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonis...
Status
Completed
Location
GSK Investigational Site
Start Date
2016-06-23
Trial ID
NCT02723955
This is a Phase 1/2, open-label, multicenter study to determine the efficac...
Status
Active Not Recruiting
Location
Local Institution - 0006
Start Date
2017-11-27
Trial ID
NCT03331198
The aim of this study is to evaluate the therapeutic effect of therapy with...
Status
Not Yet Recruiting
Location
Medimprove
Start Date
2025-05
Trial ID
NCT06937216
Treatments Being Tested
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in p...
Status
Terminated
Location
Stanford University, School of Medicine, Stanford Cancer Institute
Start Date
2019-04-04
Trial ID
NCT03682055
Treatments Being Tested